AC105 in Patients With Acute Traumatic Spinal Cord Injury (AC105)
A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Determine the Safety, Tolerability and Potential Activity of AC105 Following a Regimen of 6 Doses Over 30 Hours in Patients With Acute Traumatic Spinal Cord Injury (SCI).
Sponsor: Acorda Therapeutics
Terminated
The study was terminated by the Sponsor due to insufficient enrollment.
A PHASE2 clinical study on Acute Spinal Cord Injury, this trial is terminated or withdrawn. The trial is conducted by Acorda Therapeutics and has accumulated 8 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jul 2018 — Dec 2018 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acorda Therapeutics
- DP Clinical, Inc.
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.